Diaceutics hopes to ‘super charge’ its offering in US market after CMS approval

Irish data analytics company Diaceutics has been approved by the Centres for Medicare and Medicaid Services (CMS) to receive data on US medical claims more frequently.

The data will help to provide enhanced insight into the testing landscape for precision medicine through Diaceutics’ DXRX diagnostic commercialisation platform. The increased frequency of data feed will will help Diaceutics’s pharma and diagnostic clients to understand the evolving testing landscape in almost real time, which should help drive faster access to the right treatment.

Diaceutics chief executive Peter Keeling said the step up in data access would help "supercharge" its service in the market.

Competitive

“The most competitive companies in the diagnostic data space are those that not only can integrate very different large data sets but can deliver near real time customer insights,” he said. “Reducing the lag time for receipt of data will enable us to draw greater insight and value to help identify the best possible testing journey sooner than is currently possible, meaning treatment can be more timely and effective – a key goal for all involved in precision medicine particularly in the wake of Covid’s profound disruption to testing for cancer and other rare diseases.”